Proximagen Group plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Proximagen Group plc
FTC Rebukes Supernus Efforts To Block Sales Of Injector Pen For Use With Generic Apokyn
Agency refutes Supernus’ defense that Sage’s generic drug cartridges are ‘free-riding’ on the supply of the injector pen for its branded product. Company’s alleged exclusionary contract with pen distributor and pressure on specialty pharmacies not to provide the generic involve important antitrust issues, FTC tells court.
The Secret Sauce To BenevolentAI’s Ongoing Success
In a crowded AI-driven drug development sector, BenevolentAI stands out with its broad pipeline of drug candidates, deep pockets, and a growing partnership with AstraZeneca. Ivan Griffin, company co-founder and chief operating officer spoke with In Vivo about the formula behind the company’s successes.
Red Tree Reveals First West Coast VC Fund As It Readies For Second
Red Tree Venture Capital closed its first fund with $272m for biotech companies emerging from academic and research institutions, seeking to fill a need for early-stage funding on the West Coast.
Was Apokyn Safety Update A Missed Opportunity For Supernus To Hold Off Generic Refill Cartridge?
US FDA told the company to add a warning to the label in late January, about a month before the generic refill cartridge was approved.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Cambridge Biotechnology Ltd (CBT)
- Minster Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.